

	
AETNA BETTER HEALTH® Coverage Policy/Guideline	
Name: Tymlos	Page: 1 of 3
Effective Date: 4/21/2025	Last Review Date: 4/2025
Applies to: <div style="display: flex; justify-content: space-between;"> <div> <input checked="" type="checkbox"/> Illinois  <input checked="" type="checkbox"/> New Jersey  <input type="checkbox"/> Virginia </div> <div> <input type="checkbox"/> Florida  <input checked="" type="checkbox"/> Maryland  <input checked="" type="checkbox"/> Florida Kids </div> <div> <input checked="" type="checkbox"/> Kentucky PRMD  <input checked="" type="checkbox"/> Pennsylvania Kids </div> </div>	

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Tymlos under the patient's prescription drug benefit.

### Description:

#### FDA-Approved Indications

- A. Treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.
- B. Treatment to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.

All other indications are considered experimental/investigational and not medically necessary.

### Drug List:

Tymlos

### Policy/Guideline:

Submission of the following information is necessary to initiate the prior authorization review:

- Supporting chart notes or medical record indicating a history of fractures, T-score, and FRAX fracture probability as applicable below:

#### **A. Postmenopausal osteoporosis**

Authorization of an initial total of 12 months may be granted to postmenopausal members with osteoporosis when ANY of the following criteria are met:

1. Member has a history of fragility fractures
2. Member has a pre-treatment T-score less than or equal to -2.5 OR member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (See Appendix B) and meets ANY of the following criteria:
  - i. Member has indicators of very high fracture risk (e.g., advanced age, frailty, glucocorticoid use, very low T-scores [less than or equal to -3], or increased fall risk)
  - ii. Member has failed prior treatment with or is intolerant to previous injectable osteoporosis therapy



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Tymlos

Page: 2 of 3

Effective Date: 4/21/2025

Last Review Date: 4/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Kentucky PRMD
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Pennsylvania Kids
	<input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Florida Kids	

- iii. Member has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate (See Appendix A)

## B. Osteoporosis in men

Authorization of an initial total of 12 months may be granted to male members with osteoporosis when ANY of the following criteria are met:

1. Member has a history of an osteoporotic vertebral or hip fracture
2. Member meets BOTH of the following criteria:
  - i. Member has a pre-treatment T-score less than or equal to -2.5 OR member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (See Appendix B)
  - ii. Member has had an oral OR injectable bisphosphonate trial of at least 1-year duration OR there is a clinical reason to avoid treatment with a bisphosphonate (See Appendix A)

## CONTINUATION OF THERAPY

Authorization of 12 months may be granted for all members (including new members) who are currently receiving the requested medication through a previously authorized pharmacy or medical benefit, who have not experienced clinically significant adverse events during therapy.

NOTE: The cumulative duration of parathyroid hormone analogs (teriparatide and abaloparatide) will not exceed a total of 24 months in the member's lifetime.

## Approval Duration and Quantity Restrictions:

**Approval:** Initial and Renewal: 12 months

**Quantity Level Limit:** 1 prefilled pen (3120 mcg) per 30 days

Reference Formulary for drug specific quantity level limits

## References:

1. Tymlos [package insert]. Boston, MA: Radius Health, Inc.; February 2024.
2. Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide Vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Randomized Clinical Trial. JAMA. 2016; 316 (7): 722:733.
3. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 update. Endocr Pract. 2020;26 (Suppl 1):1-46.



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Tymlos

Page: 3 of 3

Effective Date: 4/21/2025

Last Review Date: 4/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Kentucky PRMD
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Pennsylvania Kids
	<input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Florida Kids	

4. FRAX® Fracture Risk Assessment Tool. © Centre for Metabolic Bone Diseases, University of Sheffield, UK. Available at: <https://frax.shef.ac.uk/FRAX>. Accessed October 12, 2024.
5. Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med. 2017;167(03): ITC17–ITC32.
6. Shoback D, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2020;105(3):587-594.
7. Carey JJ. What is a 'failure' of bisphosphonate therapy for osteoporosis? Cleve Clin J of Med. 2005;72(11):1033-1039.
8. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocr Metab. 2012;97(6):1802-1822.